• Completed US$320 million capital raises to support PARADIGM Trial and DurAVR® commercialization
• Advanced PARADIGM Trial recruitment, including U.S. enrollment commencement
• Presented positive clinical data from EMBARK Study and U.S. Early Feasibility Study

Anteris Technologies Global Corp. reported financial results for the quarter ended 31 March 2026 and provided a corporate update. Key highlights include completing aggregate capital raises totalling US$320 million in January 2026 to support execution of the PARADIGM Trial and advance the company toward global commercialisation of the DurAVR® THV System. The company also advanced PARADIGM Trial recruitment, supported by ongoing regulatory and operational work to activate additional countries and sites, with U.S. enrollment commencing post quarter-end. Additionally, Anteris presented clinical data from the ongoing EMBARK Study and U.S. Early Feasibility Study at industry conferences, supporting ongoing scientific engagement and exchange with the clinical community. The company's net operating cash outflows for Q1 2026 were $28.7 million, primarily attributable to clinical, regulatory and manufacturing requirements to support the PARADIGM Trial. R&D expenses of $17.5 million were driven by the upscaling of manufacturing and quality capabilities, as well as activities linked to the PARADIGM Trial, including clinical costs associated with the enrolment of additional patients and the scaling of the field-based clinical team.